Tamiflu(oseltamivir)
Ebilfumin, Oseltamivir, Tamiflu (oseltamivir) is a small molecule pharmaceutical. Oseltamivir was first approved as Tamiflu on 1999-10-27. It is used to treat human influenza in the USA. It has been approved in Europe to treat human influenza.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| respiratory tract diseases | D012140 |
Trade Name
FDA
EMA
Tamiflu (generic drugs available since 2016-08-03)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| oseltamivir | ANDA | 2024-05-03 |
| oseltamivir phosphate | ANDA | 2024-09-17 |
| oseltamivir phosphate for oral suspension | ANDA | 2023-12-27 |
| tamiflu | New Drug Application | 2024-06-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| human influenza | EFO_0007328 | D007251 | J11.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
160 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Human influenza | D007251 | EFO_0007328 | J11.1 | 14 | 31 | 24 | 26 | 18 | 106 |
| Covid-19 | D000086382 | — | — | 2 | 2 | 11 | 1 | 1 | 16 |
| Pneumonia | D011014 | EFO_0003106 | — | 1 | 1 | 3 | 3 | 2 | 10 |
| Virus diseases | D014777 | — | B34 | 1 | 2 | — | 1 | 2 | 6 |
| Respiratory tract infections | D012141 | — | J06.9 | — | 2 | 3 | 1 | 1 | 6 |
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | 1 | — | 3 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | — | 1 | — | 1 | — | 2 |
| Critical illness | D016638 | — | — | — | 1 | — | 1 | — | 2 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | 1 | — | 1 |
| St elevation myocardial infarction | D000072657 | — | — | — | — | — | 1 | — | 1 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 5 | 3 | — | 3 | 10 |
| Communicable diseases | D003141 | — | — | — | 2 | 2 | — | 2 | 6 |
| Syndrome | D013577 | — | — | — | — | 1 | — | 1 | 2 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | 1 | — | 1 | 2 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 1 | 1 | — | — | 2 |
| Influenza b virus | D009981 | — | — | — | — | 1 | — | 1 | 2 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | 1 | — | — | 1 |
| Severe acute respiratory syndrome | D045169 | EFO_0000694 | J12.81 | — | — | 1 | — | — | 1 |
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | — | 1 | — | — | 1 |
| Orthomyxoviridae infections | D009976 | EFO_0007411 | — | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 14 | 1 | — | — | 1 | 16 |
| Influenza a virus | D009980 | NCBITaxon_11320 | — | 1 | 2 | — | — | — | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 1 | — | — | 1 | 2 |
| Influenza in birds | D005585 | — | J09.X | 1 | 1 | — | — | — | 2 |
| Hematologic neoplasms | D019337 | — | — | — | 1 | — | — | — | 1 |
| Bronchiolitis obliterans | D001989 | EFO_0007183 | — | — | 1 | — | — | — | 1 |
| Interstitial lung diseases | D017563 | HP_0006530 | J84.89 | — | 1 | — | — | — | 1 |
| Bronchiolitis | D001988 | HP_0011950 | — | — | 1 | — | — | — | 1 |
| Cryptogenic organizing pneumonia | D018549 | EFO_1001300 | J84.116 | — | 1 | — | — | — | 1 |
| Bronchiolitis obliterans syndrome | D000092122 | — | — | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | — | — | 3 | — | — | — | — | 3 |
| Severe acute respiratory syndrome-related coronavirus | D045473 | NCBITaxon_227859 | — | 1 | — | — | — | — | 1 |
| Pulmonary infarction | D054060 | EFO_1001408 | — | 1 | — | — | — | — | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | 1 | — | — | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | — | — | — | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | — | — | — | 3 | 3 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | — | 2 | 2 |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | — | — | — | 2 | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 1 | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | — | — | 1 | 1 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | — | — | 1 | 1 |
Show 26 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Oseltamivir |
| INN | oseltamivir |
| Description | Oseltamivir is a cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza. It has a role as a prodrug, an EC 3.2.1.18 (exo-alpha-sialidase) inhibitor, an antiviral drug, an environmental contaminant and a xenobiotic. It is a cyclohexenecarboxylate ester, an amino acid ester, a primary amino compound and a member of acetamides. |
| Classification | Small molecule |
| Drug class | antivirals: neuraminidase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |
Identifiers
| PDB | — |
| CAS-ID | 196618-13-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1229 |
| ChEBI ID | 7798 |
| PubChem CID | 65028 |
| DrugBank | DB00198 |
| UNII ID | 20O93L6F9H (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Oseltamivir – Amneal Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tamiflu – Roche
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Oseltamivir
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 18,532 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
19,221 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use